IVVD Stock Analysis: Buy, Sell, or Hold?
IVVD - Invivyd, Inc. Common Stock
$1.00
0.05 (4.81%)
▲
5d:
+38.23%
30d:
+63.58%
90d:
-10.23%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When IVVD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: IVVD is 20.1% above its trading range ($0.83). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: IVVD is 20.1% above its trading range ($0.83). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: IVVD is currently trading at $1.00, which is considered extended relative to its 30-day fair value range of $0.58 to $0.83.
Technical Outlook: Technically, IVVD is in a strong downtrend. Immediate support is located at $0.66, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: IVVD scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+903.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IVVD is in a strong downtrend. Immediate support is located at $0.66, while resistance sits at $1.05. The stock is showing strong short-term momentum, up 4.8% recently.
Market Sentiment: IVVD scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+903.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.58 -
$0.83
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+20.1% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.8%)
- BULLISH: Trading 903.5% below Wall St target ($10.00)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.58 -
$0.83
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$1.05
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.81
Wall Street Target
$10.00
(+903.5%)
Revenue Growth (YoY)
21.2%
Profit Margin
-183.9%
Share & Embed Analysis
Last updated: August 23, 2026 7:29 PM ET
Data refreshes hourly during market hours. Next update: 8:29 PM
Data refreshes hourly during market hours. Next update: 8:29 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IVVD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$370 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$560 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$313 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
